SUBLOCADE

Indivior is a global pharmaceutical company dedicated to developing medicines for substance use disorders and serious mental illnesses. The company's flagship product, Sublocade, is the first once-monthly injectable buprenorphine formulation for the treatment of moderate-to-severe opioid use disorder. Indivior leverages its proprietary Atrigel delivery system to create long-acting injectable therapies that aim to improve patient compliance and reduce the burden of daily dosing. In addition to its addiction portfolio, the company markets Perseris for schizophrenia and Opvee for the emergency reversal of opioid overdose. Indivior continues to expand its pipeline with novel small molecules targeting the orexin and GABA systems to address unmet needs in addiction science.